An emerging blood biomarker raises a question worth drug developers’ attention: are conventional measures of disease burden ...

For pure gene silencing, siRNA offers better durability, deeper knockdown and cleaner safety, while ASOs still matter ...

For pure gene silencing, siRNA offers better durability, deeper knockdown and cleaner safety, while ASOs still matter ...

Rumors are circulating that prominent preclinical AI drug discovery biotech Isomorphic Labs is in negotiations to raise new ...

The announcement of FDA’s rare disease framework initiative marks the start of an effort patient advocates and orphan drug ...

Arrowhead’s first tau-lowering data in humans bring brain shuttles a step closer to opening the CNS to systemically ...

China is emerging as a hub for RNAi therapies, drawing Western pharmas into a wave of deals for the modality over the past ...

Companies using real-world patient data to understand disease and identify drug targets are moving beyond aggregating medical ...

Brain shuttle technology is entering a new phase. A year after BioCentury mapped a field led by protein therapeutics, much of ...

Autonomous labs could help scientists learn faster by running experiments with fewer interruptions and using the results to ...

Houston-based Duracyte is developing implants of engineered human cells that continuously produce biologics inside the body, ...

After a strong first half for biotech in 2026, the market pause in the third quarter is likely to extend through year-end ...